



Edward Price, President and CEO, PCI Synthesis

Ed Price is the Co-founder, President and CEO of PCI Synthesis (www.pcisynthesis.com), a Pharmaceutical CDMO (Contract Development and Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in New England. PCI is a clinical and commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products.

With more than 25 years of experience in chemical operations, engineering, and cGMP manufacturing, Ed has grown PCI from a basic chemical manufacturer into the leading CMO that it is today. With a robust product pipeline, PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in a variety of pharmaceutical products. In 2016, PCI was named by Inc. Magazine to the Inc. 5,000 of the fastest growing companies in the US and also named “Best NCE Manufacturer for 2016” by Global Health Magazine.

From 2014 to 2017 PCI was awarded a total of 24 CMO awards by Life Science Leader magazine. The 14 individual awards PCI received in 2017 covered all six award categories making PCI the most awarded drug substance CMO in North America and the first time an individual company was named a “Top Performer” in every category. In June of 2018 Ed led the successful sale of PCI Synthesis to Novacap LLC, a multi-billion dollar worldwide leader in the Health Care and Specialty Chemical markets based in Lyon, France.

As an industry thought-leader, Ed served as a co-chair of the New England CRO/CMO Council, is a longstanding member of the American Chemical Society and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a member of the Board of Governors for the Society of Chemical Manufacturer’s and Affiliates (SOCMA) and advises its Bulk Pharmaceutical Task Force. Numerous publications have been written about PCI Synthesis, most recently in Pharmaceutical Processing, Pharmaceutical Outsourcing, Manufacturing Chemist, Pharmaceutical Compliance Monitor, Contract Pharma, the Boston Business Journal, Mass High Tech, Chemical & Engineering News, and BioSpace.

Prior to founding the company, Ed served in numerous positions at several leading custom chemical manufacturers including ChemDesign and PolyOrganix (previously Borregaard Synthesis). He holds a B.S. in Chemical Engineering from the University of Massachusetts, Amherst and completed graduate studies in Chemical Engineering at Texas A&M University.